Comparative Pharmacology
Head-to-head clinical analysis: PREVACID versus PRILOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID versus PRILOSEC.
PREVACID vs PRILOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
Omeprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, thereby blocking the final step of gastric acid secretion.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
20 mg orally once daily before a meal for 4-8 weeks for GERD; for duodenal ulcer, 20 mg once daily for 4 weeks; for Zollinger-Ellison syndrome, initial dose 60 mg orally once daily, titrate up to 120 mg three times daily as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Terminal elimination half-life: 0.5–1 hour in healthy subjects (elimination phase); clinical context: acid suppression persists >24 hours due to irreversible binding to parietal cell H+/K+-ATPase.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Renal: ~77% as metabolites; fecal: ~20% as metabolites (biliary/fecal). Unchanged drug negligible.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor